Table 2.
The outcome of the dendritic cell vaccination strategy.
| Author, Year | Number | Median OS |
Median PFS |
6-Month PFS |
6-Month OS |
12-Month OS |
24-Month OS |
Toxicity |
|---|---|---|---|---|---|---|---|---|
| Batich, 2017 [21] | Case: 11 Control: 23 |
41.1 19.2 |
25.3 8.0 |
100 78.3 |
100 95.7 |
100 52.2 |
72.7 17.4 |
No adverse events |
| Buchroithner, 2013 [23] | Case: 19 Control: 21 |
14.6 12.7 |
89.0 62.0 |
No adverse events | ||||
| Buchroithner, 2018 [22] | Case: 34 Control: 42 |
18.8 18.9 |
66.7 71.4 |
- Thrombopenia (n = 7) - lymphopenia (n = 1) - leucopenia (n = 2) - rash (n = 2) - fatigue (n = 3) - headache (n = 2) - nausea (n = 1) |
||||
| Chang, 2011 [24] | Case: 17 Control: 63 |
17.3 12.7 |
85.1 81.0 |
64.7 55.6 |
41.2 11.1 |
- Lymphopenia (n = 17) - serum AST/ALT elevations (n = 8) - seizures (n= 3) - hydrocephalus (n = 1) |
||
| Cho, 2012 [25] | Case: 18 Control: 16 |
ND: 31.9 ND: 15.0 |
ND: 8.5 ND: 8.0 |
100 100 |
88.9 75.0 |
ND: 88.9 ND: 75.0 |
ND: 44.4 ND: 18.8 |
- abnormal liver function (n = 1) - mild lymphopenia (n = 1) |
| Jie, 2012 [26] | Case: 13 Control: 12 |
ND: 17.0 ND: 10.5 |
ND: 92.3 ND: 91.7 |
92.3 100 |
ND: 69.2 ND: 41.7 |
ND: 7.7 ND: 0.0 |
- fever (n = 2) - red papules (n = 1) |
|
| Leplina, 2007 [27] | Case: 39 Control: 80 |
74.4 52.5 |
35.9 27.5 |
No adverse events | ||||
| Muller, 2015 [28] | Case: 117 Control: 165 |
81.3 76.3 |
52.3 43.6 |
No adverse events | ||||
| Prins, 2011 [29] |
Case: 9 Control: 82 |
31.4 15.9 |
100 80 |
100 100 |
88.9 70.7 |
55.6 24.4 |
No adverse events | |
| Vik-Mo, 2013 [30] | Case: 7 Control: 10 |
100 100 |
58.7 80.0 |
71.4 30.0 |
- Fatigue (n = 7) - anorexia (n = 5) - focal epileptic seizures (n = 1) |
|||
| Wheeler, 2004 [32] | Case: 13 Control: 13 |
100 100 |
92.3 61.5 |
53.8 15.4 |
No adverse events | |||
| Wen, 2019 [31] | Case: 75 Control: 42 |
MD: 17 MD: 15 |
MD: 11.2 MD: 9.0 |
69.1 60.4 |
- Nervous system disorder (n = 4) - fatigue (n = 3) - musculoskeletal disorder (n = 1) - blood disorders (n = 6) - infections (2) - metabolic disorders (n = 9) - skin disorders (n = 8) |
|||
| Yamanaka, 2005 [36] |
Case: 18 Control: 27 |
88.6 88.6 |
61.1 59.3 |
22.2 3.7 |
No adverse events | |||
| Yao, 2018 [34] | Case: 22 Control: 21 |
MD: 17.3 MD: 10.7 |
77.2 66.7 |
- fever (n = 1) - erythema (n = 1) |
||||
| Yu, 2004 [35] | Case: 14 Control: 26 |
33.2 7.5 |
100 57.7 |
78.6 26.9 |
42.9 7.7 |
No adverse events |
Publication bias: The heterogeneity across the studies in assessing the efficacy of DCV on mid-term survival was insignificant, with I2 values ranging from 0.0 to 0.39, and Egger test excluded non-significant publication bias in the analyses.